Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same
OwnerBernhard Kohli, Uwe Konietzko +2inventors
InventorsBernhard Kohli, Uwe Konietzko, Roger Nitsch, Jan Grimm
Life of this patent
Estimating the term…
Abstract
A novel method of identifying and obtaining molecules interacting with neurodegenerative, neurological or neuropsychiatric disorder-associated proteins is provided, which is suitable for drug screening and drug development. Furthermore, drugs and drug targets for the therapeutic intervention of neurodegenerative, neurological or neuropsychiatric disorders, in particular Alzheimer's disease are described.
Claims48
A method of identifying or obtaining a molecule interacting with a neurodegenerative, neurological, or neuropsychiatric disorder-associated protein comprising:
- (a) providing the neurodegenerative, neurological, or neuropsychiatric disorder-associated protein, or a fragment thereof, containing a tag within a cell or tissue under conditions allowing complex formation;
- (b) subjecting a sample of the cell or tissue to at least one purification step;
- and
- (c) isolating the complex purified in step (b).
The method of claim 46, wherein step (d) comprises mass spectroscopy.
The method of claim 47, wherein APP or a fragment thereof is recombinantly expressed in the mouse.
The method of claim 47, wherein the mouse is the APP-TAP-AICD mouse.
(canceled)
-28. (canceled)
-31. (canceled)
A transgenic non-human animal comprising stably integrated into its genome a foreign nucleic acid molecule encoding a protein involved in the onset or development of a neurodegenerative, neurological, or neuropsychiatric disorder, wherein said encoded protein comprises a tag.
(canceled)
(canceled)
(canceled)
A method for treating a neurodegenerative, neurological, or neuropsychiatric disorder in a subject comprising administering to the subject an agent, wherein said agent
- (i) binds to a protein selected from the group consisting of the proteins referred to in tables 1, 2, 4, 5, 13, and 14 and the corresponding human orthologs, paralogs, or homologs thereof;
- or
- (ii) binds to APP and is derived from a protein as defined in (i);
- wherein such binding results in the inhibition of functions or processing patterns that contribute to central nervous system disease.
Dependencies are inferred from the claim text.